Insmed (INSM)
Health Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases.
What Insmed does
Insmed is a biopharmaceutical company developing and commercializing therapies for rare and serious diseases across three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The company markets two approved products: ARIKAYCE (amikacin liposome inhalation suspension) for nontuberculous mycobacterial (NTM) lung infections caused by MAC, and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis in patients 12 years and older. Insmed's pipeline includes clinical-stage programs such as TPIP (treprostinil palmitil inhalation) for pulmonary hypertension, INS1201 (gene therapy for Duchenne muscular dystrophy), and INS1202 (gene therapy for ALS), alongside preclinical programs in gene therapy and other modalities.
Themes: ["Rare respiratory diseases / NTM lung infection","Bronchiectasis / NCFB treatment","Pulmonary hypertension / interstitial lung disease","Gene therapy (DMD / ALS)","Rare pediatric diseases","Orphan drugs"]
Fundamentals
- Price$118.26 as of 2026-07-09 close
- Market cap$25.6B as of 2026-07-10
- 1-year return+22.6% as of 2026-07-09 close
- Net margin-144.4% as of 2026-07-10
- Gross margin+81.8% as of 2026-07-10
- ROE-130.1% as of 2026-07-10
- Debt / equity1.03 as of 2026-07-10
- Revenue growth (YoY)+115.1% as of 2026-07-10
- Revenue CAGR (3y)+35.2% SEC XBRL
- Beta0.80 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with significant accumulated deficit ($5.8B as of Q1 2026) and negative net margins (-144.44%), dependent on future product revenue growth and clinical success to achieve profitability.","ARIKAYCE approval is currently limited to refractory/limited alternative treatment patients; label expansion depends on positive ENCORE trial data (expected April 2026) and FDA approval, which carries regulatory risk.","BRINSUPRI is newly approved (August 2025 US, November 2025 EU) with limited commercial history; market adoption risk and potential impact from evolving US healthcare policies on international expansion timing."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.